Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors

NCT03387020 is registered in ClinicalTrials.gov with Pediatric Brain Tumor Consortium as lead sponsor.

NCT NCT03387020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03387020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors
Lead sponsor
Pediatric Brain Tumor Consortium
Phase
Phase 1
Overall status
Completed
Start date
January 13, 2018
Completion date
April 1, 2020
Enrollment
22 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cns embryonal tumor, not otherwise specified, malignant glioma, recurrent atypical teratoid/rhabdoid tumor, recurrent childhood ependymoma, recurrent diffuse intrinsic pontine glioma, recurrent medulloblastoma, refractory diffuse intrinsic pontine glioma